ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Oligo Hyaluronan-Coated Silica/Hydroxyapatite Degradable Nanoparticles for Targeted Cancer Treatment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 76 citations in OpenAlex.
- CD44-targeted virus-mimicking nanomedicine eliminates cancer stem cells and mitigates chemoresistance in head and neck squamous cell carcinoma.Materials today. Bio · 2025Article
- Tumor microenvironment-responsive precise delivery nanocarrier potentiating synchronous radionuclide therapy and chemotherapy against cancer.Journal of nanobiotechnology · 2025Article
- Doxorubicin- and Selenium-Incorporated Mesoporous Silica Nanoparticles as a Combination Therapy for Osteosarcoma.ACS applied nano materials · 2024Article
- Cocrystal@protein-anchoring nanococktail for combinatorially treating multidrug-resistant cancer.Acta pharmaceutica Sinica. B · 2024Article
- Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor.Materials today. Bio · 2024Article
- Application of calcium overload-based ion interference therapy in tumor treatment: strategies, outcomes, and prospects.Frontiers in pharmacology · 2024Review
- Hyaluronan with Different Molecular Weights Can Affect the Gut Microbiota and Pathogenetic Progression of Post-Intensive Care Syndrome Mice in Different Ways.International journal of molecular sciences · 2023Article
- Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer.International journal of nanomedicine · 2023Article
- Enhanced photodynamic therapy through multienzyme-like MOF for cancer treatment.Frontiers in bioengineering and biotechnology · 2023Article
- Exploiting recent trends for the synthesis and surface functionalization of mesoporous silica nanoparticles towards biomedical applications.International journal of pharmaceutics: X · 2022Review
- Tumor-targeted dual-starvation therapy based on redox-responsive micelle nanosystem with co-loaded LND and BPTES.Materials today. Bio · 2022Article
- An Overview of Antitumour Activity of Polysaccharides.Molecules (Basel, Switzerland) · 2022Review
- Connecting Calcium-Based Nanomaterials and Cancer: From Diagnosis to Therapy.Nano-micro letters · 2022Article
- Hyaluronic-Acid-Based Organic-Inorganic Composites for Biomedical Applications.Materials (Basel, Switzerland) · 2021Review
- Biodegradable calcium phosphate nanoparticles for cancer therapy.Advances in colloid and interface science · 2020Review
- Oligo Hyaluronan-Coated Silica/Hydroxyapatite Degradable Nanoparticles for Targeted Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Mechanisms of hydrogel-based microRNA delivery systems and its application strategies in targeting inflammatory diseases.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted drug delivery systems (TDDSs) provide a promising approach to overcome the side effect of traditional chemotherapy by specific tumor targeting and drug release. Hyaluronan (HA), as a selective CD44 targeting group, has been widely used in TDDSs for chemotherapy. However, different molecular weight HAs would demonstrate different binding ability to CD44, which may result in different therapeutic effects. Herein, a silica/hydroxyapatite (MSNs/HAP) hybrid carrier loaded with anticancer drug doxorubicin (DOX) (DOX@MSNs/HAP) is fabricated. HA and oligo HA (oHA) are coated onto the nanoparticles (HA-DOX@MSNs/HAP, oHA-DOX@MSNs/HAP), respectively, to investigate their performance in tumor targeting ability. oHA-DOX@MSNs/HAP shows much higher efficiency cellular uptake and drug release in tumor regions due to more effective CD44 targeting of oHA. Thus, the anticancer effect of oHA-DOX@MSNs/HAP is significantly enhanced compared to HA-DOX@MSNs/HAP, as demonstrated in a tumor-bearing mouse model. This study may enable the rational design of nanodrug systems for future tumor-targeted chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.